Endo International plc (ENDP) Expected to Announce Quarterly Sales of $680.67 Million

Share on StockTwits

Wall Street analysts expect Endo International plc (NASDAQ:ENDP) (TSE:ENL) to post $680.67 million in sales for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Endo International’s earnings, with the highest sales estimate coming in at $696.00 million and the lowest estimate coming in at $671.52 million. Endo International posted sales of $875.73 million in the same quarter last year, which suggests a negative year over year growth rate of 22.3%. The firm is scheduled to issue its next earnings report on Tuesday, August 14th.

According to Zacks, analysts expect that Endo International will report full-year sales of $2.75 billion for the current financial year, with estimates ranging from $2.71 billion to $2.78 billion. For the next year, analysts anticipate that the company will post sales of $2.76 billion per share, with estimates ranging from $2.65 billion to $2.93 billion. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Endo International.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Tuesday, May 8th. The company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.12. The business had revenue of $700.53 million during the quarter, compared to analysts’ expectations of $691.94 million. Endo International had a negative net margin of 75.58% and a positive return on equity of 143.46%. The business’s revenue for the quarter was down 32.5% compared to the same quarter last year. During the same period in the previous year, the company earned $1.23 earnings per share.

Several research analysts have issued reports on ENDP shares. JMP Securities cut shares of Endo International from an “outperform” rating to a “market perform” rating in a report on Monday, February 26th. Canaccord Genuity set a $7.00 price objective on shares of Endo International and gave the company a “hold” rating in a report on Wednesday, February 21st. BidaskClub raised shares of Endo International from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 16th. Barclays set a $9.00 price objective on shares of Endo International and gave the company a “hold” rating in a report on Saturday, March 10th. Finally, Mizuho cut shares of Endo International from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $12.00 to $7.00 in a report on Wednesday, April 4th. Three research analysts have rated the stock with a sell rating, seventeen have given a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $9.40.

Endo International stock traded up $0.23 during trading hours on Friday, hitting $6.18. The stock had a trading volume of 150,538 shares, compared to its average volume of 5,113,884. The company has a debt-to-equity ratio of -1,161.84, a quick ratio of 0.88 and a current ratio of 1.06. The stock has a market capitalization of $1.34 billion, a PE ratio of 1.61 and a beta of 0.34. Endo International has a 12-month low of $5.27 and a 12-month high of $14.15.

A number of hedge funds have recently made changes to their positions in the business. Paloma Partners Management Co bought a new position in shares of Endo International in the fourth quarter worth approximately $122,000. Oakbrook Investments LLC bought a new position in shares of Endo International in the fourth quarter worth approximately $133,000. Xact Kapitalforvaltning AB bought a new position in shares of Endo International in the fourth quarter worth approximately $157,000. Elkfork Partners LLC bought a new position in shares of Endo International in the fourth quarter worth approximately $194,000. Finally, Neuburgh Advisers LLC boosted its position in shares of Endo International by 84.2% in the first quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock worth $215,000 after purchasing an additional 16,566 shares during the period. 98.38% of the stock is owned by institutional investors and hedge funds.

Endo International Company Profile

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Get a free copy of the Zacks research report on Endo International (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply